NKGen Biotech, Inc.

NKGen Biotech, Inc., trading under the ticker GFOR, completed its business combination with Graf Acquisition Corp. IV, a blank check company sponsored by Graf Acquisition IV LLC that went public in 2021 targeting the healthcare and biotechnology sector. The September 2023 Form 8-K filing, submitted under accession number 0001104659-23-105417, reflects the closing of that de-SPAC transaction, bringing NKGen Biotech — a clinical-stage company focused on natural killer cell-based immunotherapies for cancer and neurodegenerative diseases — onto public markets. The combined entity's status moved to operating public company following the filing. Investors tracking SPAC-to-biotech transitions and clinical-stage immunotherapy plays can sign up at SpacDesk for full filing history, sponsor profiles, and deal analytics on GFOR and hundreds of comparable transactions.